Kaiser permanente's prescription drug benefit

被引：15

作者：

Levine, S ^{[1
]}

Campen, D

Millares, M

Barrueta, A

机构：

[1] Permanente Med Grp, Formulary Subcomm, Oakland, CA USA

[2] Kaiser Fdn, Hlth Plan, Oakland, CA USA

来源：

HEALTH AFFAIRS | 2000年 / 19卷 / 02期

关键词：

D O I：

10.1377/hlthaff.19.2.185

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

[No abstract available]

引用

页码：185 / 190

页数：6

共 9 条

[1]

DANZON P, 1997, PHARM PRICE REGULATI, P16

[2]

ETHEREDGE L, 1999, HLTH AFFAIRS JUL, P7

[3] Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study [J].

Go, AS ;

Hylek, EM ;

Borowsky, LH ;

Phillips, KA ;

Selby, JV ;

Singer, DE .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) :927-+

[4]

HANDLER J, 1998, PREVENTIVE CARDI FAL

[5] Just what the HMO ordered: The paradox of increasing drug costs [J].

Kleinke, JD .

HEALTH AFFAIRS, 2000, 19 (02) :78-91

[6]

KLEINKE JD, 1999, FACTORS AFFECTING GR

[7]

NEUTEL J, 1998, CARDIOVASCULAR R FEB, P49

[8]

*NOV, 1999, NOV PHARM BEN REP 19, P5

[9]

TANOUYE E, 1998, WALL STREET J 1116, pA1

← 1 →